Sent on behalf of Dr. Ed Benz
The Clinical Investigations Policy and Oversight Committee (CLINPOC) has required significant reorganization in order to become consistent with NCI guidelines and to serve the needs of DF/HCC more effectively. With the assistance of Jeffrey Clark, MD, DF/HCC Medical Director for Clinical Trials Operations, Beverly Ginsburg-Cooper, MBA, Associate Director for Administration, the DF/HCC Executive Committee, and the entire CLINPOC membership, we have reconfigured the focus and direction of this committee. Because of the substantive changes involved, we have recommended that the DF/HCC Executive Committee dissolve CLINPOC and create a new committee entitled the Clinical Investigations Leadership Committee (CLC). The DF/HCC Executive Committee has approved this recommendation, and I have asked Stephen Cannistra, MD, to chair this committee.
CLC will now serve as the major forum for discussing issues related to clinical trial implementation and conduct throughout DF/HCC. It is comprised of senior faculty and administrative leadership from all DF/HCC institutions, representing the concerns of a variety of disciplines including patient safety, scientific review, ethics, nursing, and biostatistics. This broad scope is necessary to effectively address the needs of a consortium as large and complex as DF/HCC. Because we will examine issues that have an impact on DF/HCC’s clinical investigations process, CLC is in a unique position to identify trends and systemic problems that may not be immediately obvious to other committees or individual investigators. CLC will play a central role in detecting problems, proposing solutions, and communicating its recommendations directly to the Cancer Center Director, Executive Committee, Administration, SRC and IRB leaders, and senior representatives from DF/HCC member institutions, as appropriate.
We have also elevated the former CLINPOC Audit Subcommittee to full committee status. In addition, the new Scientific Progress Review Committee (SPRC) has taken over the responsibilities once held by the CLINPOC Accrual Monitoring Subcommittee. This change was required to be consistent with NCI guidelines for Comprehensive Cancer Centers.
CLC is dedicated to serving the needs of the DF/HCC research community, especially those involving systemic issues that are difficult to solve without broad input from a variety of disciplines. If you have identified issues that might be best served by the CLC, please feel free to discuss them directly with Dr. Cannistra by emailing him at email@example.com or with any member of the CLC.
Edward J. Benz Jr., MD